Ophthalmology Executive Deb Jorn Joins pSivida to Focus on Corporate and Commercial Development
pSivida Corp. announced that Deb Jorn has joined the company as Executive Vice President of Corporate and Commercial Development, a newly created position reporting directly to Nancy Lurker, pSivida’s President and Chief Executive Officer. Ms. Jorn’s primary responsibilities will be to establish collaborations leveraging pSivida’s unique technologies and finalizing an EU partnership deal for the Company’s Durasert 3-year uveitis, which was formerly known as Medidur.
Ms. Jorn’s experience and expertise in corporate licensing, M&A and alliance management helped her build US and global pharmaceutical businesses across numerous therapeutic areas, including ophthalmology. Most recently, she was EVP and Company Chair at Valeant Pharmaceuticals and previously served as Chief Marketing Officer at Bausch + Lomb. Earlier, Ms. Jorn was Group VP of Womens’ Healthcare and Fertility at Schering Plough. She was also at Johnson & Johnson as the Worldwide VP of Internal Medicine and Early Commercial Input. She began her career at Merck and for more than 20 years held roles of progressive responsibility in a variety of functions including R&D, regulatory, sales and marketing. Ms. Jorn holds a B.A. in Biochemistry from Rutgers University and an MBA from New York University’s Stern Graduate School of Business Administration.
"Deb has an impressive track record and her knowledge of the ophthalmology market and her corporate licensing and M&A experience greatly enhance our team’s capabilities,” Ms. Lurker said in a company news release. “She is a proven leader who, in addition to her corporate licensing and M&A experience has also brought many iconic brands to market. I look forward to working with Deb as we begin the early planning for our future branding and launch of Durasert 3-year uveitis in the EU and US.”
“I am very excited about pSivida’s sustained-release drug products. I believe my pharmaceutical experience and successful track record in corporate licensing and M&A will enable us to leverage pSivida’s unique delivery technologies and prepare Durasert 3-year uveitis product for launch,” commented Ms. Jorn.
You must be logged in to leave a comment.